Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2010 in primary IgA nephropathy
CTR20231326Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-2010 in IgA nephropathy (IgAN), sponsored by Hengrui Therapeutics. Started May 2023; status: terminated.
02
Drugs
SHR-2010
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20231326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231326.